Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?
|
31821407 |
2020 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We demonstrated the association of IKZF1 polymorphism rs4132601 T/G with increased risk of ALL among Tunisian pediatric cohort, with altered phenotypic changes among ALL patients.
|
31604453 |
2019 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
CK2 inhibitor by increasing IKAROS activity significantly suppresses <i>RAG1</i> expression in ALL in an IKAROS-dependent manner.
|
31333801 |
2019 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Common CNAs involved CDKN2A/2B (30.3%), IKZF1 (27.3%), PAX5 (9.1%), RB1 (9.1%), BTG1 (6.7%), and ETV6 (6.7%), which regulate cell cycle, B lymphopoiesis, or act as tumor suppressors in ALL.
|
31112375 |
2019 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this issue of Cancer Cell, Churchman et al. add to the list of leukemia predisposition genes with the identification and characterization of germline IKZF1 variants in childhood ALL.
|
29763621 |
2018 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The multiplex ligation-dependent probe amplification (MLPA) method was used to detect the copy number alterations (CNAs) of IKAROS family zinc finger 1 (<i>IKZF1</i>), paired box 5 (<i>PAX5</i>), ETS variant 6 (<i>ETV6</i>), RB transcriptional corepressor 1 (<i>RB1</i>), BTG anti-proliferation factor 1 (<i>BTG1</i>), early B-cell factor 1 (<i>EBF1</i>), cyclin dependent kinase inhibitor 2A/2B (<i>CDKN2A/2B</i>) and cytokine receptor like factor 2 (<i>CRLF2</i>) genes in 87 adults with acute lymphoblastic leukemia (ALL) in China.
|
29552179 |
2018 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our results demonstrate that the IKAROS promotes PHF2 expression, and suggest that PHF2 <sup>low</sup> expression works with the IKAROS gene deletion to drive oncogenesis of ALL.
|
28994305 |
2018 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These results identify IKZF1 as a leukemia predisposition gene, and emphasize the importance of germline genetic variation in the development of both familial and sporadic ALL.
|
29681510 |
2018 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Patients and Methods The analysis involved 991 patients with BCP ALL treated in the Associazione Italiana Ematologia ed Oncologia Pediatrica-Berlin-Frankfurt-Muenster (AIEOP-BFM) ALL 2000 trial with complete information for copy number alterations of IKZF1, PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A, CDKN2B, Xp22.33/Yp11.31 (PAR1 region; CRLF2, CSF2RA, and IL3RA), and ERG; replication of findings involved 417 patients from the same trial.
|
29498923 |
2018 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present study examines the incidence of IKZF1, CDKN2A/B, PAX5, EBF1, ETV6, BTG1, RB1, JAK2, and Xp22.33 gene deletions/duplications associated with pediatric ALL in Iran and investigates the possible effect of these mutations on drug resistance.
|
28886309 |
2017 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recent experimental mouse modeling of B-progenitor ALL has shown that IKZF1 alterations have multiple effects, including arresting differentiation, skewing lineage of leukemia from myeloid to lymphoid, and, in Ph+ leukemia, conferring resistance to tyrosine kinase inhibitor (TKI) therapy without abrogating ABL1 inhibition.
|
27865806 |
2017 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, IKZF1 deletion is associated with high BCL6 and low BACH2 expression in B-ALL patients.
|
28030830 |
2017 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The IKZF1 SNPs, rs10235796 and rs6964969, and the CDKN2A SNP rs3731246 (previously unreported) could serve as risk markers for ALL susceptibility in Yemeni children.
|
28768142 |
2017 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
CFZ showed significantly higher activity than BTZ in the majority of ALL cell lines except for the P-glycoprotein-positive t(17;19) ALL cell lines, and IKZF1 deletion was also associated with a favorable response to CFZ treatment.
|
29236701 |
2017 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ikaros (IKZF1) functions as a master regulator of hematopoiesis and a tumor suppressor in acute lymphoblastic leukemia (ALL).
|
26912004 |
2016 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Philadelphia chromosome-like ALL is essentially heterogeneous; however, deletion mutations in the IKZF1 gene encoding the transcription factor IKAROS underlie many cases as a key factor inducing aggressive phenotypes and poor treatment responses.
|
26991355 |
2016 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Previous studies have shown evidence for association between risk of ALL and variation within IKZF1, ARID5B, CEBPE, CDKN2A, GATA3, and BM1-PIP4K2A genes.
|
26941364 |
2016 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
COBL is a novel hotspot for IKZF1 deletions in childhood acute lymphoblastic leukemia.
|
27419633 |
2016 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recent genome-wide association studies (GWAS) focusing on pediatric acute lymphoblastic leukemia (ALL), the most common malignancy in children younger than 15 years old, have found evidence that single-nucleotide polymorphisms (SNPs) in IKZF1 (7p12.2), ARID5B (10q21.2), CDKN2A (9p21.3), and CEBPE (14q11.2) are strongly associated to the risk of developing pediatric ALL.
|
27184773 |
2016 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The current case-control study evaluated variants in ARID5B (rs7089424, rs10821936), IKZF1 (rs4132601) and CEBPE (rs2239633) genes, which appear most significantly associated with risk of developing childhood B-lineage ALL.
|
27644650 |
2016 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we aimed to inspect the impact of IKZF1 gene polymorphisms and childhood ALL in a sample of Iranian population who live in south east of Iran.
|
26790447 |
2016 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our data also suggest that high CRLF2 expression works with the IKZF1 deletion to drive oncogenesis of ALL and has significance in an integrated prognostic model for adult high-risk ALL.
|
27391346 |
2016 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These SNPs are located at CDKN2A (rs3731217) and IKZF1 (rs4132601), genes frequently lost in ALL, and at CEBPE (rs2239633), ARID5B (rs7089424), PIP4K2A (rs10764338), and GATA3 (rs3824662), genes located on chromosomes gained in high-hyperdiploid ALL.
|
26575185 |
2015 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Retinoids potentiated the activity of dasatinib in mouse and human BCR-ABL1 ALL, providing an additional therapeutic option in IKZF1-mutated ALL.
|
26321221 |
2015 |
Childhood Acute Lymphoblastic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ARID5B, IKZF1 and non-genetic factors in the etiology of childhood acute lymphoblastic leukemia: the ESCALE study.
|
25806972 |
2015 |